Avacta Therapeutics Raises £3.25 Million and Secures Bond Amendment to Advance FAP-Dox Cancer Therapy
核心洞察
Avacta Therapeutics (搜索) raised £3.25 million through an oversubscribed equity placing to settle its October convertible bond repayment and strengthen its financial position.
The company secured amendments to its convertible bond terms, including deferral of quarterly repayments until October 2027 and a reduced conversion price from 88.72 pence to 75.0 pence.
CEO Christina Coughlin highlighted encouraging initial clinical activity observed in the Phase 1b trial of FAP-Dox (搜索), demonstrating confidence in the pre|CISION® platform's potential to transform cancer (搜索) treatment.
Avacta Therapeutics (搜索) has successfully raised £3.25 million through an oversubscribed equity placing and negotiated favorable amendments to its convertible bond terms, providing the oncology-focused company with enhanced financial flexibility as it advances its pre|CISION® platform technology. The developments come as the company reports encouraging initial clinical activity in its Phase 1b trial of FAP-Dox (搜索) (AVA6000) for triple negative breast cancer (搜索).
Equity Fundraising Provides Immediate Capital
The AIM-listed life sciences company completed the placing of 6.5 million new ordinary shares at 50 pence per share, generating gross proceeds of £3.25 million from high net worth investors. Zeus Capital Limited (搜索) served as sole bookrunner for the oversubscribed offering, which will result in the new shares representing approximately 1.6% of the company's enlarged share capital.
The net proceeds of approximately £3.1 million will be used to settle the October quarterly repayment of the unsecured convertible bond due on October 20, 2025. The placing shares are expected to commence trading on AIM at 8:00 am on September 12, 2025, following admission to the London Stock Exchange.
Strategic Bond Amendments Defer Payment Obligations
Avacta has secured significant amendments to its convertible bond issued by Avacta Finance Jersey Limited (搜索), providing crucial breathing room for the company's development programs. The key modifications include deferral of quarterly bond repayments and interest for January 20, 2026 and April 20, 2026 payment dates until October 20, 2027.
The conversion price of the convertible bond has been reduced from 88.72 pence to 75.0 pence, making conversion more attractive for bondholders. Additionally, the bondholder will gain acceleration rights upon either the publication of Phase 1b FAP-Dox (搜索) data readouts or by June 30, 2026, whichever occurs first.
Clinical Progress Drives Confidence
CEO Christina Coughlin expressed strong confidence in the company's clinical progress, stating: "The initial clinical activity observed in Phase 1b of the FAP-Dox (搜索) trial is highly encouraging and has further increased our confidence in the utility of our pre|CISION® platform to transform how we treat cancer (搜索)."
The bond amendments reflect the bondholder's confidence in Avacta's pre|CISION® platform, which continues to demonstrate progress both in clinical trials and laboratory development. The platform's potential spans multiple therapeutic modalities, positioning the company for potential partnership opportunities.
Conditional Requirements for Long-term Stability
The bond amendments are subject to Avacta completing a significant fundraise of at least £13 million by January 15, 2026. This funding requirement can be satisfied through various mechanisms including partnership agreements for pharmaceutical products, strategic investments, or additional equity fundraising.
Coughlin noted that the amendment terms "demonstrate our confidence in Avacta's ability to partner pre|CISION® across a number of modalities as well as our ability to source additional funding." The company enters what it describes as a pivotal commercial period with multiple catalysts expected over the coming months.
Following the placing admission, Avacta's enlarged issued share capital will total 411,048,875 ordinary shares. The company's strengthened board and management team are positioned to capitalize on opportunities enabled by the pre|CISION® technology platform as clinical data continues to mature.